Merck's (MRK) KEYTRUDA and KEYTRUDA QLEX plus Paclitaxel +/- Bevacizumab has been approved for certain adults with PD-L1+ platinum-resistant ovarian carcinoma as second or third line treatment

Merck's approval of KEYTRUDA and KEYTRUDA QLEX for treating platinum-resistant ovarian carcinoma represents a significant advance in their oncology portfolio.

Newsquawk StaffPublished On the live feed at 12 more headlines followed before this page went public
Newsquawk headlinesUTC

Secretary of State Rubio will meet Israel PM Netanyahu 09:00EST/14:00GMT at Blair House. Netanyahu will meet US President Trump at 11:00EST/16:00GMT at the White House

Bank of America (BAC) Consumer Checkpoint says consumer spending showed solid resilience in January, with total card spending +2.6% Y/Y, strongest in nearly two years, despite weather‑related disruptions

Merck's (MRK) KEYTRUDA and KEYTRUDA QLEX plus Paclitaxel +/- Bevacizumab has been approved for certain adults with PD-L1+ platinum-resistant ovarian carcinoma as second or third line treatment

US President Trump is privately considering exiting the North American trade pact, Bloomberg reports

Dutch Court maintains its October decision regarding the suspension of Nexperia's former CEO, will appoint two investigators at Nexperia on short notice

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This could enhance their competitive position in the pharmaceutical market, particularly within Europe, and may lead to positive sentiment among investors regarding MRK's growth trajectory in the biotech sector. Keep an eye on peer reactions as this move could spur further consolidation or strategic partnerships in the oncology space.

Related headlines

The whole workspace, free to try.

Try it free